Type 2

Gut bacteria and the immune system: How aging changes the microbiome and can lead to ‘inflammaging’

Retrieved on: 
Wednesday, April 3, 2024
Research, Inflammation, Inflammaging, Health, Red meat, Vitamin, Bacillota, Nutrient, Archaea, Cell, Environment, Disease, Infection, Homeostasis, Probiotic, Risk, Dysbiosis, Gastrointestinal tract, Extrapyramidal system, Tissue, Actinomycetota, Fungus, Bacteria, Virus, University, Life, Pseudomonadota, Type 2 diabetes, Diet, Nutritional science, Mucus, Immune system, Cellular senescence, Family, Stomach, Antigen, Type 2, Vaccine

Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.

Key Points: 
  • Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.
  • However, as the composition of our gut microbiome changes with age, a low level of inflammation can become constant throughout the body.
  • Let’s take a closer look at the gut microbiome and how it changes with age.

Gut microbiome imbalances in older adults

  • In fact, compared to other parts of the body, the gut microbiome has the largest number of bacteria.
  • In a healthy gut microbiome, there are four dominant families (or phyla) of microorganisms, including Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.
  • Firmicutes and Bacteroidetes make up around 80 to 90 per cent of the gut microbiota in the digestive tract.
  • Over time, the shortage of beneficial bacteria such as Firmicutes in older adults starts to compromise the integrity of their intestinal barrier, causing it to become leaky.

How inflammaging works

  • Inflammaging creates an environment that is prone to inflammation, which is caused and maintained by several factors.
  • These can include microorganism imbalances in the intestines (microbial dysbiosis), psychological stress, physical inactivity, poor nutrition and chronic infections.

Maintaining a healthy balance of gut microbiota

  • More specifically, probiotics help improve the function of the intestinal barrier and regulate immune responses by modifying the composition of the gut microbiome.
  • It is clear that the immune system has an intricate relationship with the gut microbiome.
  • A healthy and well-balanced gut microbiome will strengthen the intestinal barrier, which helps to reduce inflammation throughout the body and support the immune system.
  • To achieve this, it is important to maintain a healthy and well-balanced lifestyle as we grow older.


Narveen Jandu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Statement from Bea Bruske, President of the Canadian Labour Congress on the news about NDP/Liberal negotiations on pharmacare:

Retrieved on: 
Friday, February 23, 2024
News, Health, Type 2, Type, Woman, Heat, Retirement, NDP, New Democrats, Pharmacare, Parent, Liberal, Food, Policy, Health insurance

We are very encouraged by the news that the Liberals and New Democrats have reached a deal on pharmacare.

Key Points: 
  • We are very encouraged by the news that the Liberals and New Democrats have reached a deal on pharmacare.
  • This achievement represents the most significant enhancement to our healthcare system since the creation of public healthcare in Canada.
  • It's a milestone that will profoundly impact the lives of Canadians by making healthcare more accessible and affordable.
  • These are the struggles many Canadians face daily – not the fake outrage that Mr. Poilievre is talking about these days.

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, February 22, 2024
EMANATE, New Drug Application, Investment, Obesity, BMI, Webcast, Initiate, BBS, Stage 2, Hyperpigmentation, Documentation, Polyphagia, European, GAAP, European Medicines Agency, PCSK1, Type, Type 2, G&A, LG Chem, BV, Completeness, Shanda, Bardet–Biedl syndrome, Clinical trial, LEPR, Medicaid, IND, Prescription, Research, Hunger, Acquisition, Quarter, EMA, MC4R, FDA, Prevalence, PMDA, Patient, POMC, Body mass index, Pharmaceutical industry

-- Acquired global rights to oral MC4R agonist LB54640 from LG Chem --

Key Points: 
  • ET --
    BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: As of December 31, 2023, cash, cash equivalents and short-term investments were approximately $275.8 million, as compared to $333.3 million as of December 31, 2022.
  • S,G&A Expenses: S,G&A expenses were $32.4 million in the fourth quarter of 2023 and $117.5 million for the year ended December 31, 2023, compared to $26.3 million in the fourth quarter of 2022 and $92.0 million for the year ended December 31, 2022.
  • ET today to review its fourth quarter and year end 2023 financial results and recent business activities.

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

Retrieved on: 
Tuesday, February 20, 2024
Boston Scientific, Therapy, Close the Gap, Type 2 diabetes, Obesity, Weight loss, Cardiology, Entrepreneurship, Gap, Type 2

"Sam Conaway's proven track record in the successful launch of novel products and therapeutic procedures is a critical addition to our Board of Directors at this juncture," said Dr. Harith Rajagopalan, Co-Founder and CEO of Fractyl Health.

Key Points: 
  • "Sam Conaway's proven track record in the successful launch of novel products and therapeutic procedures is a critical addition to our Board of Directors at this juncture," said Dr. Harith Rajagopalan, Co-Founder and CEO of Fractyl Health.
  • Sales in the Cardiology Group at Boston Scientific Corporation and as Chairman of Close the Gap, the Boston Scientific Health Equity initiative.
  • "I am deeply honored and excited to join the Board of Directors at Fractyl Health, a company at the cutting edge of addressing some of the most pressing healthcare challenges of our time," said Mr. Conaway.
  • Mr. Conaway's expertise is expected to play a key role in Fractyl Health's ongoing efforts to complete its pivotal clinical studies in T2D and weight loss maintenance.

Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study

Retrieved on: 
Wednesday, March 6, 2024
Technology, General Health, Health, Hardware, MARD, American Diabetes Association, Algorithm, CGM, Know Labs, Treatment, FDA, Blood, Dielectric spectroscopy, Data, Conference, Type 2 diabetes, ATTD, Type 2, Mayo Clinic, Clinical professor, Prediabetes, Clinical trial, RF, CWD, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study.
  • Dr. Virend K. Somers of the Mayo Clinic serves as an author and co-investigator on the clinical research protocol.
  • “Despite significant efforts in the development of non-invasive blood glucose monitoring solutions, delivering a highly accurate, economical, FDA-cleared non-invasive continuous glucose monitor (CGM) still remains to be seen.
  • On the held-out test dataset, blood glucose was estimated with a MARD of 11.1 ± 2.1% relative to venous blood.

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Retrieved on: 
Tuesday, March 5, 2024
Software, Health, Diabetes, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, Clinical Trials, Tandem, HCP, CGM, Apple Watch, G6, Diabetic ketoacidosis, AID, DXCM, G7, Hypoglycemia, GLP1, Conference, Type 2 diabetes, ATTD, Type 2, Patient, Insulin, Apple, Mortality, Pharmaceutical industry

Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.

Key Points: 
  • Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.
  • Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.
  • Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023.
  • Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024.

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

Retrieved on: 
Tuesday, March 5, 2024
Software, Health, FDA, Diabetes, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, CGM, Continuity, Multimedia, MD, DXCM, A1C, Type 2 diabetes, Stelo, Type 2, Smartphone, Insulin, Glucose, Insurance, Dietary supplement

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription.
  • There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology.
  • Today, Dexcom G7 is available for them with a prescription.
  • To learn more about Stelo and do a benefits check to see if you’re eligible to get started now with Dexcom G7, visit https://www.dexcom.com/en-us/stelo .

Viz.ai Announces Successful Completion of SOC 2 Type II + HIPAA Audits for Viz.ai One Platform

Retrieved on: 
Monday, February 26, 2024
Security, Other Health, Pharmaceutical, Software, Artificial Intelligence, Networks, Medical Devices, Internet, Hospitals, Accounting, Data Management, Professional Services, Technology, Practice Management, General Health, Data Analytics, Health, Health Insurance, AICPA, Artificial intelligence, SOC 2, AI, RN, Business continuity planning, Confidentiality, Data management, DNP, HIPAA, Patient, Privacy, American Institute, Trust, Type 2, Corporation, SOC, Accountability Act

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the completion of the Service Organization Control (SOC) 2 Type II + HIPAA audit, which includes both SOC 2 and the Health Insurance Portability and Accountability Act (HIPAA).

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the completion of the Service Organization Control (SOC) 2 Type II + HIPAA audit, which includes both SOC 2 and the Health Insurance Portability and Accountability Act (HIPAA).
  • Successful completion of this auditing standard developed by the American Institute of Certified Public Accounts (AICPA), further validates Viz.ai’s focus on security, compliance and responsible AI.
  • “We are proud to have achieved SOC 2 Type II compliance for the fourth year in a row,” said Tom Vaknin, Chief Information Security Officer at Viz.ai.
  • To learn more about SOC 2 audit and request the report, please visit the Viz.ai Trust Center .

MemorialCare Medical Group and Greater Newport Physicians Nationally Recognized for Blood Pressure and Diabetes Management by American Heart Association

Retrieved on: 
Friday, March 8, 2024
Diabetes, Type 2 diabetes, Research, American Heart Association, Diet, Physician, Hospital, American Medical Association, Health, Type 2, American Heart, Nursing, Population health, Patient, Guideline, Pharmaceutical industry

These awards celebrate a commitment to controlling the blood sugar levels in patients with diabetes and accurate blood pressure measurements.

Key Points: 
  • These awards celebrate a commitment to controlling the blood sugar levels in patients with diabetes and accurate blood pressure measurements.
  • "We are honored to have been nationally recognized by the American Heart Association and American Medical Association," says Dr. David Kim, chief executive officer, MemorialCare Medical Foundation.
  • MemorialCare Medical Group and Greater Newport Physicians earned these awards by achieving an exceptional 70% or greater rate of adhering to cardiovascular-focused clinical measures and controlling high blood pressure throughout its adult patient population.
  • "The high level of care they provide daily shows MemorialCare Medical Group and Greater Newport Physician's commitment to providing quality care for our patients."

Americans Still in the Dark: New Data from MyFitnessPal Reveals Sizable Continuing Gaps in Basic Nutritional Knowledge

Retrieved on: 
Thursday, March 7, 2024
Well, Slate, Pharmacology, Diabetes, Non-alcoholic fatty liver disease, University, Gut, Doctor of Philosophy, Nutrition, MD, DSM-IV codes, Cardiovascular disease, Obesity, Overalls, MyFitnessPal, CDN, Eye, Food, Learning, Type 2 diabetes, Health, Type 2, Society, Internal medicine, Alternative medicine, Mother, Patient, Men's Health, Eating, Knowledge, Motivation, Longevity, Male, Internal, Obesity medicine, Dietary supplement

NEW YORK, March 7, 2024 /PRNewswire/ -- The beginning of a new year is when health and wellness are top of mind for consumers, but new data reveals ongoing gaps in nutrition knowledge of Americans that could be hindering their personal goals. MyFitnessPal, the leading global nutrition and food tracking app, recently conducted their Nutrition IQ 2.0 survey1, in follow up to initial results from 2022. Trends from the data show that Americans have more to learn in 2024, with the majority of Americans still unaware of the nutritional value and content in their daily diet. With the data showing that Americans' knowledge of nutrition has not deepened significantly over the past two years, MyFitnessPal formed a scientific advisory council to guide the development of nutrition content, tools, and features that support members in achieving their health and nutrition goals.

Key Points: 
  • MyFitnessPal , the leading global nutrition and food tracking app, recently conducted their Nutrition IQ 2.0 survey1, in follow up to initial results from 2022.
  • Trends from the data show that Americans have more to learn in 2024, with the majority of Americans still unaware of the nutritional value and content in their daily diet.
  • Compared to 2022, Americans are still overestimating calorie count and protein content, while underestimating fat and carb content.
  • A majority of Scott's clients are males looking to lose weight, but they're also looking to address longevity and gut health.